Dasatinib

BNF:
8.1.5
Status:
Do Not Prescribe (DNP), Red
Decision Date:
January 2017
 

Comments

RED: 

  • NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia.  (Decision date - January 2017).
  • NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia.  (Decision date - January 2017).

DO NOT PRESCRIBE (DNP):

  • NICE TA714: treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia.  (Terminated appraisal).  (Decision date - August 2021).


Do Not Prescribe (DNP) Drug Classifications

  • 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app